Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102310 · ClinicalTrials.gov registry record · Phase 2
YM443 in Subjects With Functional Dyspepsia
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 416
- Enrollment target
NCT00102310: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT00102310 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 416 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (213% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102310, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 416 participants
- Enrollment target
Study Summary
The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
Interventions
- DRUG YM443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2004-03-10 |
| Est. Completion | 2006-03-11 |
| Phase | Phase 2 |
What the finished NCT00102310 record still lists
NCT00102310 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (213% higher).
The record links to 0 conditions, and to 1 intervention - of which YM443 is the first listed.
NCT00102310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00102310 about?
NCT00102310 is a clinical study titled "YM443 in Subjects With Functional Dyspepsia". The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
What is the current status of trial NCT00102310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2004-03-10. Estimated completion is 2006-03-11.
What interventions are being tested in trial NCT00102310?
The interventions under investigation include: YM443 (DRUG).
Who is sponsoring clinical trial NCT00102310?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00102310's enrollment target sits among peer trials
416 91st of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06075745 · 416 participants · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI